# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-012227
Filing Date
2024-08-14
Accepted
2024-08-14 16:05:57
Documents
63
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | anvs-20240630x10q.htm iXBRL | 10-Q | 1105285
2 | EX-31.1 | anvs-20240630xex31d1.htm | EX-31.1 | 12909
3 | EX-32.1 | anvs-20240630xex32d1.htm | EX-32.1 | 5561
| Complete submission text file | 0001558370-24-012227.txt |  | 5340271

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
4 | EX-101.SCH | anvs-20240630.xsd | EX-101.SCH | 39637
5 | EX-101.CAL | anvs-20240630_cal.xml | EX-101.CAL | 30443
6 | EX-101.DEF | anvs-20240630_def.xml | EX-101.DEF | 144529
7 | EX-101.LAB | anvs-20240630_lab.xml | EX-101.LAB | 320387
8 | EX-101.PRE | anvs-20240630_pre.xml | EX-101.PRE | 258563
66 | EXTRACTED XBRL INSTANCE DOCUMENT | anvs-20240630x10q_htm.xml | XML | 923742

Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 241207546
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)